Xeris Biopharma Reports Second Quarter Financial Results and Upcoming Events
Achieved record net product revenue of $25.3M – a 15% increase from Q1 ’22, and a 34% increase from same period prior year on a pro forma basis Ended Q2 with $111.6M in cash, cash equivalents and short-term investments Reaffirms full-year total net product revenue of $105M-$120M; $50M in synergies by year-end, 2022 year-end cash … [Read more…]